지난해 9월 임상 결과 발표 당시에는 엔젠시스 투약군과 위약군 간의 약물 혼용 가능성을 확인했다고 주장했다.
When the clinical results were announced in September of last year, they claimed that it had confirmed the possibility of drug mixing between the Engensis-treated group and the placebo group.